Advertisement
Screener

Genprex, Inc. (GNPX) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Genprex, Inc. Research and Development Expense

Genprex, Inc. (GNPX) reported Research and Development Expense of $2.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14

  • Genprex, Inc. research and development expense for the quarter ending 2026-06-30 was $2.68M, a 7.36% increase year-over-year.
  • Genprex, Inc. research and development expense for the quarter ending 2026-03-31 was $2.75M, a 8.11% increase year-over-year.
  • Genprex, Inc. research and development expense for the quarter ending 2025-12-31 was $2.20M, a 22.62% decline year-over-year.
  • Genprex, Inc. research and development expense for the quarter ending 2025-09-30 was $2.19M, a 20.43% decline year-over-year.
  • Genprex, Inc. research and development expense for fiscal 2025 was $9.43M, a 10.50% decline from fiscal 2024.
  • Genprex, Inc. research and development expense for fiscal 2024 was $10.54M, a 40.20% decline from fiscal 2023.
  • Genprex, Inc. research and development expense for fiscal 2023 was $17.62M, a 53.05% increase from fiscal 2022.
  • Genprex, Inc. research and development expense for fiscal 2022 was $11.51M, a 28.31% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$2.68M
10-Q · filed 2026-08-14
$5.43M
10-Q · filed 2026-08-14
$7.63M
derived: sum of 3 quarters · filed 2026-08-14
$9.82M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$2.75M
10-Q · filed 2026-05-13
$4.94M
derived: sum of 2 quarters · filed 2026-05-13
$7.14M
derived: sum of 3 quarters · filed 2026-05-13
$9.63M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$2.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$4.39M
derived: sum of 2 quarters · filed 2026-03-30
$6.89M
derived: sum of 3 quarters · filed 2026-08-14
$9.43M
10-K · filed 2026-03-30
2025-09-30$2.19M
10-Q · filed 2025-11-14
$4.69M
derived: sum of 2 quarters · filed 2026-08-14
$7.23M
10-Q · filed 2025-11-14
$10.07M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$2.50M
10-Q · filed 2026-08-14
$5.04M
10-Q · filed 2026-08-14
$7.88M
derived: sum of 3 quarters · filed 2026-08-14
$10.63M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$2.54M
10-Q · filed 2026-05-13
$5.38M
derived: sum of 2 quarters · filed 2026-05-13
$8.13M
derived: sum of 3 quarters · filed 2026-05-13
$9.80M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$2.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$5.59M
derived: sum of 2 quarters · filed 2026-03-30
$7.26M
derived: sum of 3 quarters · filed 2026-03-30
$10.54M
10-K · filed 2026-03-30
2024-09-30$2.76M
10-Q · filed 2025-11-14
$4.42M
derived: sum of 2 quarters · filed 2025-11-14
$7.70M
10-Q · filed 2025-11-14
$7.70M
10-Q · filed 2024-11-13
$11.41M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$1.67M
10-Q · filed 2025-08-14
$4.94M
10-Q · filed 2025-08-14
$8.65M
derived: sum of 3 quarters · filed 2025-08-14
$13.27M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$3.27M
10-Q · filed 2025-05-12
$6.99M
derived: sum of 2 quarters · filed 2025-05-12
$11.60M
derived: sum of 3 quarters · filed 2025-05-12
$15.58M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$3.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01
$8.33M
derived: sum of 2 quarters · filed 2025-04-01
$12.31M
derived: sum of 3 quarters · filed 2025-04-01
$17.62M
10-K · filed 2025-04-01
2023-09-30$4.62M
10-Q · filed 2024-11-13
$8.59M
derived: sum of 2 quarters · filed 2024-11-13
$13.90M
10-Q · filed 2024-11-13
$17.29M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$3.98M
10-Q · filed 2024-08-09
$9.29M
10-Q · filed 2024-08-09
$12.67M
derived: sum of 3 quarters · filed 2024-08-09
$15.83M
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31$5.31M
10-Q · filed 2024-05-15
$8.70M
derived: sum of 2 quarters · filed 2024-05-15
$11.85M
derived: sum of 3 quarters · filed 2024-05-15
$14.78M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$3.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$6.54M
derived: sum of 2 quarters · filed 2024-04-01
$9.47M
derived: sum of 3 quarters · filed 2024-04-01
$11.51M
10-K · filed 2024-04-01
2022-09-30$3.16M
10-Q · filed 2023-11-14
$3.59M
10-Q · filed 2022-11-14
$6.08M
derived: sum of 2 quarters · filed 2023-11-14
$8.12M
10-Q · filed 2023-11-14
$8.19M
10-Q · filed 2022-11-14
$11.97M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$2.93M
10-Q · filed 2023-08-21
$2.74M
10-Q · filed 2022-08-12
$4.97M
10-Q · filed 2023-08-21
$4.60M
10-Q · filed 2022-08-12
$8.81M
derived: sum of 3 quarters · filed 2023-08-21
$10.24M
derived: sum of 4 quarters · filed 2023-08-21
2022-03-31$2.04M
10-Q · filed 2023-05-22
$1.86M
10-Q · filed 2022-05-13
$5.88M
derived: sum of 2 quarters · filed 2023-05-22
$7.32M
derived: sum of 3 quarters · filed 2023-05-22
$8.84M
derived: sum of 4 quarters · filed 2023-05-22
2021-12-31$3.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$5.28M
derived: sum of 2 quarters · filed 2023-03-31
$6.80M
derived: sum of 3 quarters · filed 2023-03-31
$8.97M
10-K · filed 2023-03-31
$8.61M
10-K · filed 2022-03-30
2021-09-30$1.43M
10-Q · filed 2022-11-14
$2.96M
derived: sum of 2 quarters · filed 2022-11-14
$5.13M
10-Q · filed 2022-11-14
$7.32M
derived: sum of 4 quarters · filed 2023-03-31
2021-06-30$1.53M
10-Q · filed 2022-08-12
$3.70M
10-Q · filed 2022-08-12
$5.89M
derived: sum of 3 quarters · filed 2023-03-31
$7.24M
derived: sum of 4 quarters · filed 2023-03-31
2021-03-31$2.04M
10-K · filed 2023-03-31
$2.17M
10-Q · filed 2021-05-17
$4.36M
derived: sum of 2 quarters · filed 2023-03-31
$5.71M
derived: sum of 3 quarters · filed 2023-03-31
$7.87M
derived: sum of 4 quarters · filed 2023-03-31
2020-12-31$2.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
$3.67M
derived: sum of 2 quarters · filed 2022-03-30
$5.83M
derived: sum of 3 quarters · filed 2022-03-30
$7.30M
10-K · filed 2022-03-30
2020-09-30$1.35M
10-Q · filed 2021-11-15
$3.51M
derived: sum of 2 quarters · filed 2021-11-15
$4.98M
10-Q · filed 2021-11-15
$5.47M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$2.16M
10-Q · filed 2021-08-13
$3.63M
10-Q · filed 2021-08-13
$4.12M
derived: sum of 3 quarters · filed 2021-08-13
$4.59M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31$1.48M
10-Q · filed 2021-05-17
$1.97M
derived: sum of 2 quarters · filed 2021-05-17
$2.43M
derived: sum of 3 quarters · filed 2021-05-17
$2.94M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$489.58K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26
$956.92K
derived: sum of 2 quarters · filed 2021-03-26
$1.46M
derived: sum of 3 quarters · filed 2021-03-26
$1.97M
10-K · filed 2021-03-26
2019-09-30$467.34K
10-Q · filed 2020-11-12
$969.38K
derived: sum of 2 quarters · filed 2020-11-12
$1.48M
10-Q · filed 2020-11-12
$1.79M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$502.04K
10-Q · filed 2020-08-11
$1.01M
10-Q · filed 2020-08-11
$1.33M
derived: sum of 3 quarters · filed 2020-08-11
$1.82M
derived: sum of 4 quarters · filed 2020-08-11
2019-03-31$508.04K
10-Q · filed 2020-05-14
$825.19K
derived: sum of 2 quarters · filed 2020-05-14
$1.31M
derived: sum of 3 quarters · filed 2020-05-14
$1.43M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$317.15K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30
$806.84K
derived: sum of 2 quarters · filed 2020-03-30
$919.81K
derived: sum of 3 quarters · filed 2020-03-30
$971.43K
10-K · filed 2020-03-30
2018-09-30$489.69K
10-Q · filed 2019-11-14
$602.66K
derived: sum of 2 quarters · filed 2019-11-14
$654.28K
10-Q · filed 2019-11-14
$715.35K
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$112.97K
10-Q · filed 2019-08-13
$164.59K
10-Q · filed 2019-08-13
$225.66K
derived: sum of 3 quarters · filed 2019-08-13
$281.18K
derived: sum of 4 quarters · filed 2019-08-13
2018-03-31$51.62K
10-Q/A · filed 2019-05-20
$112.69K
derived: sum of 2 quarters · filed 2019-05-20
$168.21K
derived: sum of 3 quarters · filed 2019-05-20
$273.19K
derived: sum of 4 quarters · filed 2019-05-20
2017-12-31$61.07K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
$116.59K
derived: sum of 2 quarters · filed 2019-04-01
$221.57K
derived: sum of 3 quarters · filed 2019-04-01
$289.93K
10-K · filed 2019-04-01
2017-09-30$55.52K
10-Q · filed 2018-11-14
$160.50K
derived: sum of 2 quarters · filed 2018-11-14
$228.86K
10-Q · filed 2018-11-14
$358.20K
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$104.98K
10-Q · filed 2018-08-14
$173.34K
10-Q · filed 2018-08-14
$302.68K
derived: sum of 3 quarters · filed 2018-08-14
$392.58K
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31$68.36K
10-Q · filed 2018-05-15
$197.70K
derived: sum of 2 quarters · filed 2018-05-15
$287.60K
derived: sum of 3 quarters · filed 2018-05-15
2016-12-31$129.34K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17
$219.23K
derived: sum of 2 quarters · filed 2018-04-17
$354.88K
10-K · filed 2018-04-17
2016-09-30$89.90K
10-Q · filed 2017-12-05
$225.55K
10-Q · filed 2017-12-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
Sunshine Biopharma Inc. (SBFM)$0.003B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02